Cancer
Radio Luminescence
Therapy
Unlocking the Potential of
Photodynamic/Ultraviolet Light Therapy
(PDT/UV-A) in Deep Tumor Treatment
Confidential and Proprietary
The Team
5 0 Ye a r s o f C u m u l a t i v e E x p e r i e n c e
in Healthcare & business Management
Founders
You-Yeon Won
Rachel Kim
Purdue Professor of
Chemical Engineering
10+ years in
Corporate Finance
Management Team
Confidential and Proprietary
Wade Lange
Scott Clark
30 years experience in
Healthcare (Big Pharma,
CRO, Biotech Startup
3 years experience in
Healthcare (CRO)
2
The Problem
X-Ray Therapy: standard treatment
for almost half of cancer patients
Limitations:
•
•
•
•
Confidential and Proprietary
Tissue Burn, Cell Damage
Multiple costly hospital visits
Not for frail patients
Radio resistant tumors
3
The Solution
T h e L o d o s Te c h n o l o g y
CaWO4
RLNPs
1) Inject RLNPs directly
into the tumor
3) Activated RLNPs emit
UV light and destroy the tumor
2) EBR (X-Ray)
Activates RLNPs
C o m b i n a t i o n o f X - R a y & U V L i g h t d e s t r o y Tu m o r
Without Deep Penetration into Surrounding Tissue
Confidential and Proprietary
4
Market & Lodos Potential
T h e L o d o s Te c h n o l o g y
Cancer Incidence by Major Region
Cancer Incidence by Tumor Type
Addressable Patient Population
5.28M New Cases 2017
>90% are Solid Tumors
2.5M Patients
0
5
13%
1.69M
2.61M
Breast
11%
US
Japan
Prostate
5.28 M
Colo-rectal
51%
EU
12%
Lung
Other
0.98M
ESTIMATED NEW
CANCER CASES
13%
PATIENTS RECEIVING
EXTERNAL BEAM
RADIATION
(EBR OR X-RAY)
2.5 M
Source: ACS, EUCAN, Ministry of Health in Japan
Lodos Revenue Potential - If 10% of the EBR population were treated with Lodos technology, at an
average price range of $4000 -$5,000, the potential sales would be between $1.0B - $1.3B/yr.
Confidential and Proprietary
5
Competition
Current & Future Radiation Approaches
CURRENT
Form
Radiation
Chemotherapy
FUTURE
Nanobiotics
Magforce
Confidential and Proprietary
Mechanism of Action
X-Rays Alone
Limitations
Systemic Side Effects
X-Rays plus Chemotherapy Drugs
Additive X-Ray & Chemo side effects
Enhances radiation within tumor
Damages healthy tissue near tumor
(Nanoparticles release free electrons when
x-ray is activated)
Magnetically-Generated Heat
(Alternating magnetic current heats nanoparticles,
killing nearby cells)
Less effective against Radio-resistant tumors
Damages healthy tissue near tumor
6
Business Model
Development & Partnership
IND Inflection:
Preferred Time to Partner
Development Stage
Preclinical
Development Cost
$3M
$11 M
Development Time
2 Years
3 Years
Phase I
Phase II
Phase III
Commercialization
Cost effective regulatory pathway with clear value inflection point
Confidential and Proprietary
7
Marketing
Already Ahead
• Limited number of radiation oncologists
(~5000 each in US and Europe)
• Allows for sales coverage with a small sales force
• Attractive to potential partner organizations
• Does not require purchase of new capital
• Does not require changes to practice patterns
Confidential and Proprietary
8
3-Year Milestones
Projection of Achievable Goals
• Complete In-Progress Proof-of-Concept Studies (<12 months)
• Clinical Protocol Development (12-18 months)
• Formulation Optimization (12-18 months)
• GLP/GMP Manufacturing Capability (18-24 months)
• GLP/GMP Preclinical Trials (24-36 months)
• IND Application for Human Clinical Testing (36 months)
Confidential and Proprietary
9
Use of Funds
Progression and Upkeep
• Patent and Licensing Upkeep (~$10K)
• Laboratory Studies (~$10K)
• Proof-of-Concept Completion
• Formula Optimization
• Development of Manufacturing Capability
Confidential and Proprietary
10
Lodos Theranostics
[Point of Contact]
[Phone Number]
[Email Address]
[Website]